T2 Biosystems pulls in $40M in Series E funding round

03/29/2013 | American City Business Journals

A Series E funding round led by Goldman Sachs has brought in $40 million for T2 Biosystems. The Lexington, Mass.-based company will use the money to develop and commercialize its T2Candida test, which can detect Candida fungal infections known to cause sepsis from whole blood samples in under two hours.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI